Larvol Delta - Viracta-Therapeutics-Announces-Final-Phase-1b2-Data-Showing-Promising-and-Durable-Signal-of-Efficacy-for-Nanaval-in-RelapsedRefractory-EpsteinBarr-VirusPositive-Lymphoma-in-an-Oral-Presentation-at-ASH-2021

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

nanatinostat (VRx-3996) - Viracta Therap

https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-final-phase-1b2-data-showing-promising-and-durable-signal-of-efficacy-for-nana-val-in-relapsedrefractory-epstein-barr-virus-positive-lymphoma-in-an-oral-presentation-at-ash-2021-301443175.html

Dec 13, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next